Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice

References

• Mirand A, Henquell C, Archimbaud C, Ughetto S, Antona D, Bailly JL, Peigue-Lafeuille H. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clini Microbiol Infect 2012; 18:E110-8; PMID:22404077; http://dx.doi.org/10.1111/j.1469-0691.2012.03789.x
   PubMed Web of Science ®Google Scholar
• Lu QB, Zhang XA, Wo Y, Xu HM, Li XJ, Wang XJ, Ding SJ, Chen XD, He C, Liu LJ, et al. Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009–2011. PLoS One 2012; 7:e52073; PMID:23272213; http://dx.doi.org/10.1371/journal.pone.0052073
   PubMed Web of Science ®Google Scholar
• Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10:778-90; PMID:20961813; http://dx.doi.org/10.1016/S1473-3099(10)70194-8
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, Liang Z. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccines Immunother 2014; 10:360-7; PMID:24231751; http://dx.doi.org/10.1080/21645515.2015.1008870
   PubMed Web of Science ®Google Scholar
• Yi L, Lu J, Kung HF, He ML. The virology and developments toward control of human enterovirus 71. Critical Rev Microbiol 2011; 37:313-27; PMID:21651436; http://dx.doi.org/10.3109/1040841X.2011.580723
   PubMed Web of Science ®Google Scholar
• McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. Fems Microbiol Rev 2002; 26:91-107; PMID:12007645; http://dx.doi.org/10.1111/j.1574-6976.2002.tb00601.x
   PubMed Web of Science ®Google Scholar
• Iwai M, Masaki A, Hasegawa S, Obara M, Horimoto E, Nakamura K, Tanaka Y, Endo K, Tanaka K, Ueda J, et al. Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Japan J Infect Dis 2009; 62:254-9; PMID:19628900
   PubMed Web of Science ®Google Scholar
• Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, Ning HC, Chung PW, Kang CM. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 1999; 18:1092-6; PMID:10608631; http://dx.doi.org/10.1097/00006454-199912000-00013
   PubMed Web of Science ®Google Scholar
• Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974; 129:304-9; PMID:4361245; http://dx.doi.org/10.1093/infdis/129.3.304
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, Nishio O. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol 2002; 46:621-7; PMID:12437029; http://dx.doi.org/10.1111/j.1348-0421.2002.tb02743.x
   PubMed Web of Science ®Google Scholar
• Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:929-35; PMID:10498487; http://dx.doi.org/10.1056/NEJM199909233411301
   PubMed Web of Science ®Google Scholar
• Bendig JW, Fleming DM. Epidemiological, virological, and clinical features of an epidemic of hand, foot, and mouth disease in England and Wales. Commun Dis Rep CDR Rev 1996; 6:R81-6; PMID:8664928
   PubMedGoogle Scholar
• NNDRS. http://wwwnhfpcgovcn/zhuzhan/yqxx/listshtml 2014
   Google Scholar
• Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381:2024-32; PMID:23726161; http://dx.doi.org/10.1016/S0140-6736(13)61049-1
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi.org/10.1016/S0140-6736(07)60946-5
   PubMed Web of Science ®Google Scholar
• Liu H, Ma Y, Wang H, Liu Q. Quantitative evaluation of the effect of the hepatitis B vaccine based on the HBsAg- and anti-HBs-positive rates in the Chinese population over the last 33 years. Vaccine 2012; 30:3483-7; PMID:22433962; http://dx.doi.org/10.1016/j.vaccine.2012.02.053
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov ( Identifier NCT01897701)
   Google Scholar
• Sun S, Jiang L, Liang Z, Mao Q, Su W, Zhang H, Li X, Jin J, Xu L, Zhao D, et al. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice. Hum Vaccines Immunother 2014; 10:2885-95; PMID:25483672; http://dx.doi.org/10.4161/hv.29823
   PubMed Web of Science ®Google Scholar
• Mao Q, Dong C, Li X, Gao Q, Guo Z, Yao X, Wang Y, Gao F, Li F, Xu M, et al. Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice. PLoS One 2012; 7:e46043; PMID:23029378; http://dx.doi.org/10.1371/journal.pone.0046043
   PubMed Web of Science ®Google Scholar
• Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, Cai F, Gao Z, McMinn PC. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011; 29:4829-38; PMID:21550375; http://dx.doi.org/10.1016/j.vaccine.2011.04.070
   PubMed Web of Science ®Google Scholar
• Giersing BK, Dubovsky F, Saul A, Denamur F, Minor P, Meade B. Potency assay design for adjuvanted recombinant proteins as malaria vaccines. Vaccine 2006; 24:4264-70; PMID:16767804; http://dx.doi.org/10.1016/j.vaccine.2006.01.005
   PubMed Web of Science ®Google Scholar
• DJ. F. Probit analysis. 3rd ed. London: Cambrige university press. 1971
   Google Scholar
• DJ. F. Statistical methodology in biological assay. 3rd ed. London: Charles Griffin and Company. 1978
   Google Scholar
• Sokol RR RF. Biometry: the principles and practice of statistics in biological research. 3rd ed. Newyork: W.H. Freeman and Company. 1995
   Google Scholar
• Gaines RE, Tydeman MS. Iterative weighted regression analysis of logit responses: a computer program for analysis of bioassays and immunoassays. Comput Programs Biomed 1982; 15:13-21; PMID:7128120; http://dx.doi.org/10.1016/0010-468X(82)90052-6
   PubMedGoogle Scholar
• Commission EP. Statistical analysis of results of bioligical assays and test. European Pharmacopoeia, 5th ed. Strasburg: Council of Europe, 475-504
   Google Scholar
• 2010 P. Pharmacopoeia of the People's Republic of China ( 2010 Edition):
   Google Scholar
• Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014; 370:818-28; PMID:24571754; http://dx.doi.org/10.1056/NEJMoa1304923
   PubMed Web of Science ®Google Scholar
• Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014; 370:829-37; PMID:24571755; http://dx.doi.org/10.1056/NEJMoa1303224
   PubMed Web of Science ®Google Scholar
• Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, Chou AH, Chang JY, Jiang RH, Hsieh YC, et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013; 31:2471-6; PMID:23541623; http://dx.doi.org/10.1016/j.vaccine.2013.03.015
   PubMed Web of Science ®Google Scholar
• Li HY, Han JF, Qin CF, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 2013; 31:3281-7; PMID:23726823; http://dx.doi.org/10.1016/j.vaccine.2013.05.019
   PubMed Web of Science ®Google Scholar
• Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, Lin AN, Chiang BL. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 2012; 30:1305-12; PMID:22214888; http://dx.doi.org/10.1016/j.vaccine.2011.12.081
   PubMed Web of Science ®Google Scholar
• Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008; 26:1855-62; PMID:18329759; http://dx.doi.org/10.1016/j.vaccine.2008.01.058
   PubMed Web of Science ®Google Scholar
• Liang Z, Wang J. EV71 vaccine, an invaluable gift for children. Clin Translat Immunol 2014; 3:e28; PMID:25505956; http://dx.doi.org/10.1038/cti.2014.24
   PubMedGoogle Scholar
• de Moura WC, de Araujo HP, Cabello PH, Romijn PC, Leite JP. Potency evaluation of rabies vaccine for human use: the impact of the reduction in the number of animals per dilution. J Virol Methods 2009; 158:84-92; PMID:19428574; http://dx.doi.org/10.1016/j.jviromet.2009.01.017
   PubMed Web of Science ®Google Scholar
• Leslie DE, Nicholson S, Dimitrakakis M, Johnston N, Gust ID. Humoral immune responses in mice using gamma inulin preparations as adjuvants for hepatitis B vaccines. Immunol Cell Biol 1990; 68 (Pt 2):107-12; PMID:1696560; http://dx.doi.org/10.1038/icb.1990.15
   PubMed Web of Science ®Google Scholar
• Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, Ge SX, Xian YL, Pang SQ, Ng MH, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 2005; 23:2893-901; PMID:15780738; http://dx.doi.org/10.1016/j.vaccine.2004.11.064
   PubMed Web of Science ®Google Scholar
• Li SW, Zhao Q, Wu T, Chen S, Zhang J, Xia NS. The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccines Immunother 2015:11(4):908-14; PMID:25714510
   PubMed Web of Science ®Google Scholar
• Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, et al. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011; 29:9668-74; PMID:22015395; http://dx.doi.org/10.1016/j.vaccine.2011.10.018
   PubMed Web of Science ®Google Scholar
• Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001; 20:895-904; PMID:11738755; http://dx.doi.org/10.1016/S0264-410X(01)00385-1
   PubMed Web of Science ®Google Scholar
• Chiu CH, Chu C, He CC, Lin TY. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microb infect 2006; 8:1671-8; PMID:16815726; http://dx.doi.org/10.1016/j.micinf.2006.01.021
   PubMed Web of Science ®Google Scholar
• Huang BY, Wang XP, Tang WJ, Wang WL, Ruan L. The 50% effective dose (ED50a) of seasonal spilt influenza vaccine in mice. Chin J Exp Clin Virol 2011; 25:92-5; PMID:21863626
   PubMedGoogle Scholar
• Einstein MH, Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, Blatter MM, Lalezari J, David MP, Lin L, Struyf F, et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: End-of-study analysis of a Phase III randomized trial. Hum Vaccines Immunother 2014; 10:3435-45; PMID:25483701; http://dx.doi.org/10.4161/hv.36121
   PubMed Web of Science ®Google Scholar
• Einstein MH, Levin MJ, Chatterjee A, Chakhtoura N, Takacs P, Catteau G, Dessy FJ, Moris P, Lin L, Struyf F, et al. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study. Hum Vaccines Immunother 2014; 10:3455-65; PMID:25483700; http://dx.doi.org/10.4161/hv.36117
   PubMed Web of Science ®Google Scholar
• Li X, Fan P, Jin J, Su W, An D, Xu L, Sun S, Zhang Y, Meng X, Gao F, et al. Establishment of cell lines with increased susceptibility to EV71/CA16 by stable overexpression of SCARB2. Virol J 2013; 10:250; PMID:23919614; http://dx.doi.org/10.1186/1743-422X-10-250
   PubMed Web of Science ®Google Scholar
• Wu X, Mao Q, Yao X, Chen P, Chen X, Shao J, Sun S, Zhang Y, Meng X, Gao F, et al. Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71. PLoS One 2013; 8:e64116; PMID:23755115; http://dx.doi.org/10.1371/journal.pone.0064116
   PubMed Web of Science ®Google Scholar
• Jin J, Xu L, Guo S, Sun S, Zhang S, Zhu C, Kong W, Jiang C. Safe and Objective Assay of Enterovirus 71 Neutraliziong Antibodies Via Pseudovirus Chem Res Chinese Universities 2012; 28:91-95
   Google Scholar
• Zhang H, An D, Liu W, Mao Q, Jin J, Xu L, Sun S, Jiang L, Li X, Shao J, et al. Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay. PLoS One 2014; 9:e100545; PMID:24964084; http://dx.doi.org/10.1371/journal.pone.0100545
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 2012; 86:11967-76; PMID:22951825; http://dx.doi.org/10.1128/JVI.00902-12
   PubMed Web of Science ®Google Scholar